RGNX at a glance
REGENXBIO Inc. (RGNX, SEC CIK 1590877) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), REGENXBIO Inc. (RGNX) reported revenue of $170.4 million (up 104.5% from FY2024) and a net loss of $193.9 million. Diluted EPS was -$3.76.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding REGENXBIO Inc. (RGNX) shares worth $303.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Ciongoli Gregory Austin on August 27, 2026 of 53,407 shares at $9.36 per share.
- In the last 90 days, RGNX insiders reported 2 open-market purchases ($949K) and 0 open-market sales ($0) on Form 4, a net purchase of $949K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $170.4M
- +104.5% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$949K
- 13F holders
- 27 funds
- $303.0M · +0 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Risk factors section not provided; supplied text begins with Item 2 and contains no risk-factor disclosures
- Newly adopted Rule 10b5-1 plan: director David C. Stump, sale of 25,000 securities, adopted June 18, 2026
- Loan amendment: first amendment to REGENXBIO RS LLC loan agreement dated April 28, 2026
AI summary of the RGNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $39.0 million payment from Sarepta due within 10 days of settlement effectiveness
- Settlement resolves all patent litigation involving ELEVIDYS and REGENXBIO’s 617 and 274 patents
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Gregory Ciongoli elected independent Class II director through 2029 annual meeting
- Audit Committee and Nominating and Corporate Governance Committee appointments
Item 7.01: Regulation FD Disclosure
- FDA clinical hold on RGX-121 Phase I/II/III trial for MPS II, also known as Hunter Syndrome
- No near-term resubmission expected for RGX-121 BLA, delaying potential regulatory approval
Item 8.01: Other Events
- FDA clinical hold on RGX-121 Phase I/II/III trial for MPS II
- Near-term RGX-121 BLA resubmission no longer expected
AI summaries of RGNX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RGNX
Don't miss the next RGNX filing
- Alerts as it files. A push when RGNX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RGNX, by share count.
- Ask anything. An AI agent that reads every RGNX filing and answers with sources.
RGNX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Chan Mitchell | F | Sep 1, 2026 | 4,902 | $9.32 |
| Malzahn Craig | F | Sep 1, 2026 | 234 | $9.32 |
| Ciongoli Gregory Austin | Buy | Aug 27, 2026 | 53,407 | $9.36 |
| Ciongoli Gregory Austin | Buy | Aug 26, 2026 | 49,196 | $9.14 |
| Ciongoli Gregory Austin | A | Aug 25, 2026 | 69,609 | - |
| Ciongoli Gregory Austin | A | Aug 25, 2026 | 15,432 | - |
| Christmas Patrick J. | F | Aug 1, 2026 | 4,699 | $9.69 |
| PAKOLA STEVE | F | Aug 1, 2026 | 7,468 | $9.69 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $83.3M | $170.4M |
| Operating Income | - | -$233.3M | -$161.2M |
| Net Income | -$263.5M | -$227.1M | -$193.9M |
| Op. Margin | - | -280.0% | -94.6% |
| Net Margin | - | -272.5% | -113.8% |
| Balance Sheet | |||
| Total Assets | $574.0M | $466.0M | $453.0M |
| Equity | - | $259.7M | $102.7M |
| ROE | - | -87.5% | -188.7% |
| Per Share | |||
| EPS | $-6.02 | $-4.59 | $-3.76 |
| Cash Flow | |||
| Operating CF | - | -$173.1M | -$124.0M |
| CapEx | $10.0M | $2.4M | $2.4M |
Source: XBRL data in REGENXBIO Inc. (RGNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate RGNX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $303.0M |
| Q1 2026 | 27 | $200.8M |
| Q4 2025 | 25 | $339.5M |
| Q3 2025 | 25 | $272.2M |
| Q2 2025 | 26 | $198.1M |
| Q1 2025 | 21 | $124.8M |
| Q4 2024 | 19 | $78.6M |
| Q3 2024 | 17 | $64.8M |
- BlackRock+614.6K (+11%)
- D.E. Shaw & Co+426.8K (+149%)
- Vanguard Portfolio Management LLC+336.7K (+33%)
- AQR Capital Management+326.6K (+31%)
- State Street Corp+239.7K (+9%)
- JPMorgan Chase & Co−1.27M (-36%)
- Goldman Sachs Group−418.0K (-23%)
- Dimensional Fund Advisors−278.8K (-28%)
- Morgan Stanley−112.9K (-5%)
- Ameriprise Financial−100.3K (-50%)
- Citadel Advisors LLC+669.0K
- Prudential Financial−12.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RGNX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | May 12, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RGNX SEC filings: frequently asked questions
Are RGNX insiders buying or selling?
In the last 90 days, REGENXBIO Inc. (RGNX) officers, directors and 10% owners reported 2 open-market purchases worth $949,381 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RGNX stock?
As of June 30, 2026, the largest REGENXBIO Inc. (RGNX) holders among the 13F filers tracked by SignalX were BlackRock ($76.6 million), State Street Corp ($35.6 million), JPMorgan Chase & Co ($26.2 million), Vanguard Capital Management LLC ($25.2 million), Morgan Stanley ($23.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RGNX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), REGENXBIO Inc. (RGNX) reported revenue of $170.4 million (up 104.5% from FY2024) and a net loss of $193.9 million. Diluted EPS was -$3.76. The figures come from the XBRL data in the 10-K.
What did RGNX report in its latest 8-K?
REGENXBIO Inc. (RGNX) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $39.0 million payment from Sarepta due within 10 days of settlement effectiveness.
What are the latest RGNX SEC filings?
REGENXBIO Inc. (RGNX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 3, 2026.
What is RGNX's SEC CIK number?
REGENXBIO Inc. (RGNX)'s SEC Central Index Key (CIK) is 1590877. EDGAR lists every RGNX filing under that number.
Ask anything about RGNX
The research agent reads RGNX's filings, financials, insider trades and 13F holders, then answers with sources.